We primarily focused on the alterations of the ASXL1 gene to investigate whether ASXL1 biallelic inactivation would occur in MDS with isolated del(20q) and to elucidate its unique biological and prognostic characteristics in the patient cohort. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.